Conversely, the Veh/CIS group demonstrated a significant increase in urinary KIM-1 levels from baseline after just one dose of cisplatin (average 299-fold increase from baseline; p < 0.01) and these levels were significantly higher than all three other treatment groups (p < 0.01; Fig. 4A). This evidence concerns the gene HAVCR1 and in situ carcinoma.